The 64 rating InvestorsObserver gives to Enlivex Therapeutics Ltd (ENLV) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 78 percent of stocks in the Biotechnology industry, ENLVs 64 overall rating means the stock scores better than 64 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 64 means the stock is more attractive than 64 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Enlivex Therapeutics Ltd (ENLV) stock is trading at $8.32 as of 11:57 AM on Thursday, Dec 31, a loss of -$0.90, or -9.76% from the previous closing price of $9.22. The stock has traded between $8.27 and $9.10 so far today. Volume today is light. So far 125,199 shares have traded compared to average volume of 320,151 shares.

Click Here to get the full Stock Score Report on Enlivex Therapeutics Ltd (ENLV) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Excerpt from:
Is Enlivex Therapeutics Ltd (ENLV) the Top Pick in the Biotechnology Industry? - InvestorsObserver